SIDE EFFECTS OF IMMUNOMODULATORS ON THE BODY.
Abstract
Immunomodulators are widely used to regulate immune system activity, either by enhancing or suppressing immune responses. While these drugs are beneficial in treating autoimmune diseases, infections, and cancer, they are also associated with various side effects. This article reviews the adverse effects of immunomodulators on the human body, including immunosuppression, increased susceptibility to infections, allergic reactions, and organ-specific toxicities. Furthermore, the impact of long-term use, potential drug interactions, and strategies for mitigating side effects are discussed. A better understanding of these risks is crucial for optimizing therapeutic outcomes and ensuring patient safety.
References
1. Sandborn, W. J., Feagan, B. G., Hanauer, S., et al. (2020). Safety and efficacy of JAK inhibitors in ulcerative colitis and Crohn’s disease. New England Journal of Medicine, 382(10), 918-928.
2. D’Haens, G., Reinisch, W., Panés, J., et al. (2020). Long-term safety and effectiveness of TNF inhibitors in inflammatory bowel disease. Gastroenterology, 158(4), 1000-1012.
3. Solomon, D. H., Curtis, J. R., Yang, F., et al. (2019). The risk of serious infections associated with biologic and targeted synthetic DMARDs in rheumatoid arthritis patients. Annals of Internal Medicine, 170(1), 8-17.
4. Strangfeld, A., Eveslage, M., Schneider, M., et al. (2017). Risk of infections in patients with rheumatoid arthritis treated with biologic DMARDs. Arthritis & Rheumatology, 69(3), 437-447.
5. Winthrop, K. L., Mariette, X., Silva, J. T., et al. (2021). Tuberculosis and other opportunistic infections associated with the use of TNF inhibitors. The Lancet Rheumatology, 3(5), e328-e341.
6. López-González, R., León, L., Loza, E., et al. (2018). Cancer risk in patients with rheumatoid arthritis treated with biologic therapy. Rheumatology, 57(9), 1536-1545.
7. Singh, J. A., Saag, K. G., Bridges, S. L., et al. (2016). 2015 American College of Rheumatology guidelines for the treatment of rheumatoid arthritis. Arthritis & Rheumatology, 68(1), 1-26.
